RxDoctor Payments Data

Renee Rubinstein, MD

Family Medicine · Coraopolis, PANPI 1619102233

Payments from drug & device makers

$5,286in general payments, 2019–2025

Across 354 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$681
  • Biodelivery Sciences International, Inc.$561
  • Collegium Pharmaceutical, Inc.$319
  • Boehringer Ingelheim$256
  • Pfizer$230
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,286 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,221
Medicare patients
19
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl113$101,653
Trelegy ElliptaFluticasone/Umeclidin/Vilanter127$81,975
JardianceEmpagliflozin84$56,528
OzempicSemaglutide49$49,749
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl237$30,661
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$22,681
TradjentaLinagliptin22$15,763
XareltoRivaroxaban23$14,723
EliquisApixaban21$14,380
MyrbetriqMirabegron30$13,116
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$11,976
Nurtec OdtRimegepant Sulfate11$10,345
Gabapentin439$5,715
MovantikNaloxegol Oxalate12$5,233
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen173$4,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$1,312$104,655176 claims
Collegium Pharmaceutical, Inc.Belbuca$319$101,653113 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$256$84,267131 claims
Novo NordiskOzempic$97$49,74949 claims
PfizerEliquis, Nurtec Odt$230$24,72532 claims
Johnson & JohnsonXarelto$63$14,72323 claims
Astellas Pharma US IncMyrbetriq$42$13,11630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Coraopolis

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →